ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.18
-0.13%
US Tech 100
19,491.20
-0.45%
S&P 500
5,737.91
-0.13%
US Dollar vs CAD
1.35168
0.29%
Bitcoin
65,785.41
0.92%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Organon and Co (OGN)

  7. Organon and Co (OGN) News

OGN

Organon (OGN)

Organon and Co
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:OGN
DateTimeSourceHeadlineSymbolCompany
09/26/20248:50AMPR Newswire (Canada)Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in CanadaNYSE:OGNOrganon and Co
09/26/20248:49AMPR Newswire (Canada)Organon Canada et l'Alberta Women's Health Foundation s'unissent pour accroître la sensibilisation et prôner l'accès universel à la contraception au CanadaNYSE:OGNOrganon and Co
09/23/20243:21PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
09/19/20241:30PMBusiness WireオルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1%を取得NYSE:OGNOrganon and Co
09/19/20247:00AMBusiness WireOrganon erwirbt Dermavant und dessen innovative dermatologische Behandlung VTAMA® (Tapinarof) Creme, 1 %NYSE:OGNOrganon and Co
09/19/20247:00AMBusiness WireOrganon acquiert Dermavant et sa thérapie dermatologique innovante, la crème VTAMA® (tapinarof), 1 %NYSE:OGNOrganon and Co
09/18/20246:30AMBusiness WireOrganon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NYSE:OGNOrganon and Co
09/18/20246:30AMGlobeNewswire Inc.Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NYSE:OGNOrganon and Co
09/05/20243:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
09/05/20243:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
09/05/20243:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
09/05/20243:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
09/05/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
09/05/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
08/20/20247:13PMBusiness Wireオルガノンとリリーが片頭痛治療薬の商業化契約を拡大、11の新しい市場に参入NYSE:OGNOrganon and Co
08/20/20244:06PMBusiness WireOrganon und Lilly erweitern Migräne-Vermarktungsvereinbarung auf 11 weitere MärkteNYSE:OGNOrganon and Co
08/20/20242:34PMBusiness WireOrganon y Lilly amplían su acuerdo de comercialización para la migraña a otros 11 mercadosNYSE:OGNOrganon and Co
08/20/20249:20AMBusiness WireOrganon et Lilly élargissent l'accord de commercialisation pour la migraine à 11 marchés supplémentairesNYSE:OGNOrganon and Co
08/20/20246:30AMBusiness WireOrganon & Lilly Expand Migraine Commercialization Agreement to 11 Additional MarketsNYSE:OGNOrganon and Co
08/07/20247:07AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:OGNOrganon and Co
08/06/20246:39AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
08/06/20246:30AMBusiness WireOrganon Reports Results for the Second Quarter Ended June 30, 2024NYSE:OGNOrganon and Co
08/06/20244:49AMIH Market NewsUS Index Futures Rise After Market Sell-off, Oil Prices Trim LossesNYSE:OGNOrganon and Co
07/09/20246:30AMBusiness WireOrganon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024NYSE:OGNOrganon and Co
06/11/20242:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
06/11/20242:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
06/11/20242:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
06/06/20246:00AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
05/24/202412:59PMBusiness WireL’Agence européenne des médicaments (EMA) entérine les dépôts de Henlius et d’Organon pour le candidat biosimilaire HLX14 de Prolia ® et Xgeva ® (denosumab)NYSE:OGNOrganon and Co
05/24/202412:59PMBusiness WireEuropäische Arzneimittel-Agentur (EMA) validiert Einreichungen von Henlius und Organon für den Prolia ® und Xgeva ® (Denosumab) Biosimilar-Kandidaten HLX14NYSE:OGNOrganon and Co
 Showing the most relevant articles for your search:NYSE:OGN

Your Recent History

NASDAQ
AAYMDXX
Bofa Finance Llc Issuer ...
NASDAQ
DMAT
Global X Disruptive Mate...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved